Abstract Submissions

Key Dates and Deadlines
19 August Call for Abstracts Open
1 October Call for Abstracts Close
2 October Call for Late Breaking Abstracts Open
4 - 18 October Abstract Review
Late October Abstract Notifications Sent
14 January Call for Late Breaking Abstracts Close

Submission Guidelines

The abstract character limit is 4,000 with a minimum requirement of 50 characters. Please ensure that your submission is indicative of significant scientific work, a major update, and/or significant follow-up on established procedures and/or research. All abstract submissions are required to contain the following information for consideration and review:

  • Abstract Title
  • Purpose
  • Materials and Methods
  • Results
  • Conclusions

SUBMIT TODAY

Presentation Types

Oral

Abstracts submitted and accepted as this type will be presented by the presenting author during one of the two plenary afternoon oral abstract sessions.

E-Posters

Abstracts submitted and accepted as this type will be displayed on as virtual e-posters at the 2025 Annual Scientific Meeting in Las Vegas, Nevada. Accepted e-posters will not have dedicated presentation times, rather authors are encouraged to showcase their e-posters throughout the meeting during dedicated hours throughout the conference.

Categories

  • Basic/Translational Science
  • Chest and Thoracic
  • Education
  • Equity, Access, and Ethics
  • Genitourinary
  • HCC
  • Imaging
  • Industry1
  • Liver Metastases
  • Musculoskeletal
  • Pain/Palliation
  • Technology
  • Trials in Progress2
  • Other

1This category is reserved for industry-developed research and/or updates submitted by corporate entities. These abstracts will be considered separately from research developed by primary investigators and academic teams.

2See below for guidelines and policies regarding the submission of a “Trial in Progress” Abstract Submission

Abstract Policies and Procedures

Trials in Progress Policy

The Trials in Progress Category provides a unique opportunity for researchers to present ongoing trials at the SIO Annual Scientific Meeting.

Any phase (I, II, or III) trial that is ongoing, started enrolling patients or has completely enrolled, and has not yet reached prespecified endpoints for analysis may be considered for inclusion in the Trials in Progress submission category. Inclusion of results would be at the discretion of investigators. Presentation of preliminary results is not required for submission or acceptance.

All submissions will be reviewed for appropriateness by the SIO Annual Scientific Meeting Planning Committee. Accepted submissions will be notified of their presentation type.

Abstract Submissions for Trials in Progress should include Background, Methods, and Preliminary Results (optional, not required for acceptance):

Background:

  • Scientific background/rationale for the trial
  • Correlative studies of particular interest

Methods:

  • Trial design and statistical methods
  • Treatment or intervention planned
  • Major eligibility criteria
  • Clinical trial registration number (required)
  • Enrollment status

Preliminary Results (not required for acceptance):

  • Demographic, safety, and preliminary efficacy data (if appropriate for presentation).

What is not permissible in a Trials in Progress Abstract Submission:

  • Proprietary drug name
  • Information about pricing, fees, or reimbursement related to trial participation

Prior Presentation/Publication Abstract Submission Policy

SIO does not restrict the submission of abstracts that have been presented at prior meetings, or published prior to the 2025 Annual Scientific Meeting. If your submission has been presented prior to the 2025 Annual Scientific Meeting, please ensure you are adhering to the policies and procedures of the respective organization. SIO reserves the right to assign priority scoring to debut abstract presentations.

Embargo Policy and Information

All 2025 Annual Scientific Meeting Abstracts will be made public at the start of the conference, Thursday, 29 January 2025 at 7:00 am PST. Once an abstract has been made public, you may distribute a press release. SIO reserves the right to distribute press releases in advance of the release date above regarding submitted and accepted notable research.

Resubmission Policy for SIO Abstracts to Other Meetings

The process by which SIO Abstracts are submitted to other meetings is governed by the other meeting organizer. SIO does not prohibit the submission of previously accepted abstracts to other meetings however, it is strongly encouraged that submitting authors notify meeting organizers of their previous acceptance/presentation to SIO meetings.

Late-Breaking Abstracts

The SIO late-breaking abstract policy allows for the submission of late-breaking data and research which must contain information with results that were not yet discovered or available on the regular abstract submission deadline of 1 October 2024. Submissions for late-breaking abstracts will be announced following the regular abstract submission deadline on 14 January 2025.

Notification regarding late-breaking abstract’s acceptance or rejection will be sent to the submitter by 17 January 2025. Late-breaking abstracts should contain new information, which may include either:

  • Results which were not fully known or available on the regular submission deadline
  • Work that has been submitted for publication

Withdrawals and No-Show Policy

Acceptance of an abstract for any oral presentation obligates the author to attend the 2025 Annual Scientific Meeting to present in person. If circumstances prevent the presenting author’s attendance, the author must arrange for the work to be presented by a substitute, preferably a co-author. If you wish to withdraw your abstract, you must submit your request in writing by Tuesday, 7 January 2025 to education@sio-central.org and include the abstract title and presenting author’s name.

On rare occasions, selected presenters fail to show up without notifying the Society of Interventional Oncology. When presenters do not attend as planned, the efforts of the Scientific Chair and Program Committee to provide a quality program are diminished, significant costs are imposed, and the audience is unnecessarily disappointed. SIO staff will audit abstracts for no-shows. Failure to comply with these policies may result in ineligibility for participation in future SIO meetings.

Questions

Contact SIO at education@sio-central.org or call (202) 367-1164.